Literature DB >> 8174054

Postoperative radiation therapy for malignant tumors of minor salivary glands. Outcome and patterns of failure.

A S Garden1, R S Weber, K K Ang, W H Morrison, J Matre, L J Peters.   

Abstract

BACKGROUND: In the treatment of major salivary gland cancers, the addition of adjuvant postoperative radiation therapy for patients with high risk features has been shown to reduce the incidence of local failure. This retrospective study was done to determine the effectiveness of this approach for minor salivary gland cancers, to document patterns of failure, and to define prognostic variables for treatment outcome.
METHODS: Between 1961 and 1990, 160 patients received postoperative radiation at the University of Texas M. D. Anderson Cancer Center (UTMDACC) after gross total removal of their tumors. These operations ranged from excisional biopsies to craniofacial resections with orbital exenterations depending on the original site and size of the tumor. The primary tumor site was in the oral cavity-oropharynx in 111 patients and in the nasal cavity or paranasal sinuses in 46 patients. The most prevalent histologic type was adenoid cystic carcinoma (71%). Microscopic positive margins were present in 64 (40%) patients. Half of the patients had pathologic evidence of perineural invasion. Radiation therapy techniques varied, depending on the site and extent of disease and the era of treatment. Doses ranged from 50 to 75 Gy (median, 60 Gy; mean 59.2 Gy). Follow-up for surviving patients ranged from 24 to 270 months (median, 110 months).
RESULTS: Fifty-seven (36%) patients experienced disease relapse. Nineteen (12%) patients had a local recurrence: 6 within 5 years of treatment, 8 between 5 and 10 years, and 5 after 10 years. Regional failures occurred in 3 of 13 patients with initially node-positive disease but were uncommon (less than 5%) in patients with node-negative disease, regardless of elective neck treatments. Distant metastases developed in 43 patients, mostly (79%) within 5 years of treatment. Actuarial overall survival rates at 5, 10, and 15 years were 81%, 65%, and 43%, respectively. Complications occurred in 51 patients and were of three predominate types: hearing loss (26 patients), ocular injury (15 patients), and bone exposure/necrosis (12 patients). Improved techniques, including better immobilization, customized beam shaping, and treating multiple fields per day, have substantially reduced the risk of serious complications during the past decade.
CONCLUSIONS: Postoperative radiation therapy is effective in preventing local recurrence in most patients with minor salivary gland tumors after gross total excision. When local failure occurs, it tends to be a late event. For most patients, the authors recommend a postoperative dose of 60 Gy in 30 fractions to the operative bed; if there is named nerve invasion, the path of the nerve is treated electively to its ganglion.

Entities:  

Mesh:

Year:  1994        PMID: 8174054     DOI: 10.1002/1097-0142(19940515)73:10<2563::aid-cncr2820731018>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  30 in total

1.  Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy.

Authors:  Trevor M Feinstein; Stephen Y Lai; Diana Lenzner; William Gooding; Robert L Ferris; Jennifer R Grandis; Eugene N Myers; Jonas T Johnson; Dwight E Heron; Athanassios Argiris
Journal:  Head Neck       Date:  2011-01-31       Impact factor: 3.147

Review 2.  Review of clinical experience with ion beam radiotherapy.

Authors:  A D Jensen; M W Münter; J Debus
Journal:  Br J Radiol       Date:  2011-03-22       Impact factor: 3.039

3.  Sinonasal malignancies: long term follow up after surgical management-an analysis of outcomes.

Authors:  K Devaraja; Kapil Sikka; Rajeev Kumar; Alok Thakar
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2014-06-29

4.  Malignant minor salivary gland tumors: a retrospective study of 27 cases.

Authors:  Astrid L D Kruse; Klaus W Grätz; Joachim A Obwegeser; Heinz-Theo Lübbers
Journal:  Oral Maxillofac Surg       Date:  2010-12

5.  Competing causes of death and medical comorbidities among patients with human papillomavirus-positive vs human papillomavirus-negative oropharyngeal carcinoma and impact on adherence to radiotherapy.

Authors:  Clayton B Hess; Dominique L Rash; Megan E Daly; D Gregory Farwell; John Bishop; Andrew T Vaughan; Machelle D Wilson; Allen M Chen
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-04       Impact factor: 6.223

6.  Adenoid cystic carcinoma of the nasal cavity and paranasal sinuses: a meta-analysis.

Authors:  Moran Amit; Yoav Binenbaum; Kanika Sharma; Naomi Ramer; Ramer Naomi; Ilana Ramer; Ramer Ilana; Abib Agbetoba; Agbetoba Abib; Brett Miles; Xinjie Yang; Delin Lei; Kristine Bjoerndal; Bjoerndal Kristine; Christian Godballe; Godballe Christian; Thomas Mücke; Mücke Thomas; Klaus-Dietrich Wolff; Wolff Klaus-Dietrich; Dan Fliss; André M Eckardt; Chiara Copelli; Copelli Chiara; Enrico Sesenna; Frank Palmer; Palmer Frank; Snehal Patel; Ziv Gil
Journal:  J Neurol Surg B Skull Base       Date:  2013-05-15

7.  Radiation therapy in the treatment of minor salivary gland tumors.

Authors:  Lucas R Salgado; Daniel E Spratt; Nadeem Riaz; Paul B Romesser; Suzanne Wolden; Shyam Rao; Christine Chin; Julian C Hong; Richard Wong; Nancy Y Lee
Journal:  Am J Clin Oncol       Date:  2014-10       Impact factor: 2.339

8.  Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC.

Authors:  Alexandra D Jensen; Anna Nikoghosyan; Christine Windemuth-Kieselbach; Jürgen Debus; Marc W Münter
Journal:  BMC Cancer       Date:  2010-10-11       Impact factor: 4.430

9.  Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.

Authors:  S J Wong; T Karrison; D N Hayes; M S Kies; K J Cullen; T Tanvetyanon; A Argiris; N Takebe; D Lim; N F Saba; F P Worden; J Gilbert; H J Lenz; A R A Razak; J D Roberts; E E Vokes; E E W Cohen
Journal:  Ann Oncol       Date:  2015-11-23       Impact factor: 32.976

10.  Tumour response following high-dose intratumoural application of Viscum album on a patient with adenoid cystic carcinoma.

Authors:  Paul Georg Werthmann; Dieter Helling; Peter Heusser; Gunver Sophia Kienle
Journal:  BMJ Case Rep       Date:  2014-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.